News - Takeda Pharmaceuticals

Filter

Current filters:

Takeda Pharmaceuticals

Popular Filters

1 to 25 of 177 results

Jury finds in favor of Takeda in diabetes drug Actos case

23-05-2014

The US subsidiary of Japan’s largest drugmaker, Takeda Pharmaceuticals, yesterday announced that in…

ActosDiabetesLegalPharmaceuticalTakeda PharmaceuticalsUSA

US FDA thumbs up for Takeda’s Entyvio for ulcerative colitis and Crohn's disease

US FDA thumbs up for Takeda’s Entyvio for ulcerative colitis and Crohn's disease

21-05-2014

The US Food and Drug Administration yesterday approved Entyvio (vedolizumab) injection, from Japan’s…

EntyvioGastro-intestinalsPharmaceuticalRegulationTakeda PharmaceuticalsUSA

JPMA sanctions against Takeda over promotional activities for candesartan in Japan

09-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has received notice of sanctions imposed by…

Asia-PacificBlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

08-04-2014

US biotech firm Seattle Genetics says it will receive milestone payments from Japan’s Takeda Pharmaceutical…

AdcetrisAsia-PacificBiotechnologyFinancialMarkets & MarketingOncologySeattle GeneticsSouth AmericaTakeda Pharmaceuticals

Mersana in deal with Takeda to develop ADCs

Mersana in deal with Takeda to develop ADCs

07-04-2014

Privately-held US biotech firm Mersana Therapeutics has entered into a collaboration agreement with Japanese…

Antibody-drug conjugateBiotechnologyBusiness FinanceHealth Medical PharmaHealth Medical PharmaLicensingMajorMersana TherapeuticsMillennium PharmaceuticalsOncologyResearchTakeda Pharmaceuticals

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

Takeda gets positive CHMP opinion for Entyvio for UC and Crohn’s disease

21-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, today received a positive opinion form the European…

EntyvioEuropeGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Actavis challenges Multaq and Colcrys patents

02-03-2014

Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

Takeda’s new diabetes drug Vipidia debuts in UK

26-02-2014

Japan’s largest drugmaker Takeda Pharmaceuticals this morning launched its new type 2 diabetes drug…

alogliptinDiabetesMarkets & MarketingNorthern EuropePharmaceuticalTakeda PharmaceuticalsUKVipidia

Takeda re-aligns marketing system in Japan

24-02-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it decided to re-align its marketing system in…

Asia-PacificJapanManagementMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Lundbeck’s Brintellix available in US pharmacies for depression

Lundbeck’s Brintellix available in US pharmacies for depression

22-01-2014

Lundbeck (LUN: CO) and Takeda Pharmaceutical (TYO: 4502) jointly announced today that Brintellix (vortioxetine)…

BrintellixLundbeckMarkets & MarketingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsUSA

Takeda's lymphoma drug Adcetris approved in Japan

Takeda's lymphoma drug Adcetris approved in Japan

18-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical has received approval from the country’s Ministry…

AdcetrisFinancialOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Takeda appointments former GSK exec as head if CNS research

Takeda appointments former GSK exec as head if CNS research

15-01-2014

Takeda Pharmaceutical, Japan’s largest drug company, has appointed Emiliangelo Ratti as head of its…

BoardroomManagementPharmaceuticalTakeda Pharmaceuticals

Takeda to sell BIKEN varicella vaccine in Japan

Takeda to sell BIKEN varicella vaccine in Japan

15-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has reached agreement with the Research Foundation…

Asia-PacificMarkets & MarketingPharmaceuticalTakeda PharmaceuticalsVaccines

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

08-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical revealed today that vedolizumab), an investigational…

Asia-PacificGastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

27-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has decided voluntarily to terminate the development…

DiabetesfasiglifamGastro-intestinalsNorth AmericaPharmaceuticalRegulationResearchTakeda PharmaceuticalsUSAvedolizumab

Takeda collaboration with Medicines for Malaria Venture

Takeda collaboration with Medicines for Malaria Venture

26-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has entered into agreements with Medicines for Malaria…

DSM265ELQ300PharmaceuticalResearchTakeda PharmaceuticalsTropical diseases

Takeda sets sights on Israeli pharma market, with new subsidiary

Takeda sets sights on Israeli pharma market, with new subsidiary

18-12-2013

Through a European subsidiary, Japan’s largest drugmaker Takeda Pharmaceuticals today announced further…

ManagementMarkets & MarketingPharmaceuticalRest of the WorldTakeda Pharmaceuticals

1 to 25 of 177 results

Back to top